Condition

Estrogen Receptor Positive

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 43 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials43

Recruiting1

Common interventions25

Lead sponsors shown15

Clinical trials

43 shown

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted TherapyNCT04692103 · 2021-07-10

ACTIVE_NOT_RECRUITING

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05

Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast CancerNCT03091842 · 2019-07-29

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast CancerNCT03831711 · 2019-03-19

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisNCT03691493 · 2019-02-08

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid TumorsNCT03725436 · 2019-01-24

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal AtrophyNCT03666819 · 2018-09-10

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerNCT03377101 · 2018-08-07

Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer SurvivorsNCT03523195 · 2018-04-18

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast CancerNCT03359954 · 2017-11-16

ACTIVE_NOT_RECRUITING

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor CellsNCT03070002 · 2017-10-19

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerNCT03213041 · 2017-09-14

Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial CancerNCT03042897 · 2017-09-08

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerNCT03128619 · 2017-08-02

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast CancerNCT03132467 · 2017-06-13

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the BreastNCT02993159 · 2017-05-31

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerNCT02648477 · 2016-03-28

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerNCT02536794 · 2016-01-14

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After SurgeryNCT02526498 · 2015-07-15

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerNCT02457910 · 2015-06-01

Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)NCT02186015 · 2015-02-01

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryNCT02219789 · 2014-12-05

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerNCT02202746 · 2014-09-09

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsNCT02152943 · 2014-07-17

Broccoli Sprout Extract in Treating Patients With Breast CancerNCT01753908 · 2013-05-21

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing SurgeryNCT01754519 · 2013-05-01

Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast CancerNCT01846091 · 2013-04-09

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerNCT01776008 · 2013-01-01

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast CancerNCT01750073 · 2012-12-07

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsNCT01522820 · 2012-03-01

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerNCT01697293 · 2012-01-01

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast CancerNCT01928186 · 2011-09-01

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerNCT01344031 · 2011-04-21

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerNCT01319539 · 2011-04-01

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerNCT01281163 · 2011-01-01

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsNCT01281150 · 2011-01-01

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerNCT01149356 · 2010-10-01

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted TherapyNCT02149173 · 2010-09-15

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerNCT00785291 · 2008-10-13

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-PositiveNCT00390455 · 2006-09-15

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TamoxifenNCT00118157 · 2005-05-01

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast CancerNCT00338728 · 2003-10-03

Common interventions

Leading sponsors

National Cancer Institute (NCI)10 M.D. Anderson Cancer Center5 Northwestern University4 Mayo Clinic3 Roswell Park Cancer Institute3 University of Washington3 University of Southern California2 Andrei Iagaru1 City of Hope Medical Center1 Clovis Oncology, Inc.1 Emory University1 Fred Hutchinson Cancer Center1 Jonsson Comprehensive Cancer Center1 Loyola University1 Prescient Therapeutics, Ltd.1

Trial status mix

COMPLETED25

TERMINATED11

WITHDRAWN4

ACTIVE_NOT_RECRUITING2

RECRUITING1

Phase mix

PHASE222

PHASE114

NA6

EARLY_PHASE12

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.